79098-98-9

Basic information

• Product Name: tert-butyl 4-(2-aMinobenzylaMino)piperidine-1-carboxylate
• Synonyms: tert-butyl 4-(2-aMinobenzylaMino)piperidine-1-carboxylate;1-Boc-4-[[(2-aminophenyl)methyl]amino]piperidine
• CAS NO: 79098-98-9
• Molecular Formula: C₁₇H₂₇N₃O₂
• Molecular Weight: 305.41518
• Mol File: 79098-98-9.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: tert-butyl 4-(2-aMinobenzylaMino)piperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 4-(2-aMinobenzylaMino)piperidine-1-carboxylate(79098-98-9)
• EPA Substance Registry System: tert-butyl 4-(2-aMinobenzylaMino)piperidine-1-carboxylate(79098-98-9)

Safety Data

• Hazardous Substances Data: 79098-98-9(Hazardous Substances Data)

Usage

General Description

Tert-butyl 4-(2-aminobenzylamino)piperidine-1-carboxylate is a chemical compound featuring a tert-butyl group, and a piperidine ring with a carboxylate functional group. Additionally, it contains an amino group attached to a benzyl group. It is commonly used in pharmaceutical research and drug development due to its potential as a building block in the synthesis of various biologically active compounds. This chemical may have relevance in the development of new drugs for conditions such as neurological disorders, cancer, and infectious diseases. Furthermore, it is important to handle this compound with care due to its potential for toxicological effects and environmental hazards.

Upstream product

• 87120-79-4 tert-butyl 4-((2-nitrobenzyl)amino)piperidine-1-carboxylate 
• 87120-72-7 1-(tert-butoxycarbonyl)-4-aminopiperidine 
• 552-89-6 2-nitro-benzaldehyde 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 4403-69-4 2-amino-1-benzylamine 

Downstream Products

• 960221-97-0 tert-butyl 4-(2-oxo-1,2,3,4-tetrahydroquinazolin-3-yl)piperidine-1-carboxylate 
• 79106-65-3 3-{1-[2-(3,4-Dimethoxy-phenyl)-2-oxo-ethyl]-piperidin-4-yl}-3,4-dihydro-quinazolin-2-yl-cyanamide 
• 79106-71-1 3-{1-[2-(3,4-Dimethoxy-phenyl)-2-hydroxy-ethyl]-piperidin-4-yl}-3,4-dihydro-quinazolin-2-yl-cyanamide 
• 79106-67-5 3-{1-[2-Oxo-2-(3,4,5-trimethoxy-phenyl)-ethyl]-piperidin-4-yl}-3,4-dihydro-quinazolin-2-yl-cyanamide 
• 79106-66-4 3-{1-[2-(3,4-Dimethoxy-phenyl)-1-methyl-2-oxo-ethyl]-piperidin-4-yl}-3,4-dihydro-quinazolin-2-yl-cyanamide 
• 79106-73-3 3-{1-[2-Hydroxy-2-(3,4,5-trimethoxy-phenyl)-ethyl]-piperidin-4-yl}-3,4-dihydro-quinazolin-2-yl-cyanamide 
• 79106-72-2 3-{1-[2-(3,4-Dimethoxy-phenyl)-2-hydroxy-1-methyl-ethyl]-piperidin-4-yl}-3,4-dihydro-quinazolin-2-yl-cyanamide 
• 79106-68-6 3-{1-[1-Methyl-2-oxo-2-(3,4,5-trimethoxy-phenyl)-ethyl]-piperidin-4-yl}-3,4-dihydro-quinazolin-2-yl-cyanamide 
• 79122-28-4 3-{1-[2-Hydroxy-1-methyl-2-(3,4,5-trimethoxy-phenyl)-ethyl]-piperidin-4-yl}-3,4-dihydro-quinazolin-2-yl-cyanamide 
• 79098-75-2 3-piperidin-4-yl-3,4-dihydro-1H-quinazoline-2-one 

Relevant articles and documents

1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

The present invention relates to 1,3,4-oxadiazole derivative compounds having a histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, a use thereof in preparation of a medicament, a pharmaceutical composition comprising the same, a therapeutic method using the composition, and a method for preparing the same, and the 1,3,4-oxadiazole derivative compounds are represented by a following chemical formula (I).

CGRP receptor antagonists

The present invention relates to CGRP receptor antagonists, pharmaceutical compositions thereof, and methods therewith for treating CGRP receptor-mediated diseases and conditions.

BIARYL KETONE-SUBSTITUTED PIPERIDINES

Biaryl ketone-substituted piperidines of the following Formulas are provided:, and in which the variables are as described herein. Such compounds may be used to modulate calcitonin gene-related peptide (CGRP) receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions responsive to CGRP modulation in humans, domesticated companion animals and livestock animals, including headache such as migraine. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such compounds for receptor localization studies and various in vitro assays.